MAPK1 and head and neck squamous cell carcinoma: Moreover, Kong et al. found an association between MEK/ERK upregulation and cisplatin resistance suggesting a role for the combined use of cisplatin with MEK inhibitors for patients with upregulated MAPK/ERK signalling in HNSCC.45